CD38‐Targeted Theranostics of Lymphoma with 89 Zr/ 177 Lu‐Labeled Daratumumab-Reference-Cited by-同舟云学术

CD38‐Targeted Theranostics of Lymphoma with 89 Zr/ 177 Lu‐Labeled Daratumumab

Published:2021-03-15 Issue:10 Volume:8 Page:2001879
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Adv. Sci.

Author:

Kang Lei¹²,Li Cuicui¹,Rosenkrans Zachary T.³,Huo Nan⁴,Chen Zhao¹,Ehlerding Emily B.²,Huo Yan¹,Ferreira Carolina A.²,Barnhart Todd E.²,Engle Jonathan W.²,Wang Rongfu¹,Jiang Dawei²⁵,Xu Xiaojie⁴,Cai Weibo²³^ORCID

Affiliation:

1. Department of Nuclear Medicine Peking University First Hospital Beijing 100034 China

2. Departments of Radiology and Medical Physics University of Wisconsin – Madison Madison WI 53705 USA

3. Department of Pharmaceutical Sciences University of Wisconsin – Madison Madison WI 53705 USA

4. Department of Medical Molecular Biology Beijing Institute of Biotechnology Beijing 100850 China

5. Department of Nuclear Medicine Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Funder

National Institutes of Health

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202001879

Reference38 articles.

1. Hodgkin lymphoma: A review and update on recent progress

2. Cancer statistics, 2018

3. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

4. A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies

5. Immuno-PET for Clinical Theranostic Approaches

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a Novel Peptide-Based PET Tracer [⁶⁸Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma;Journal of Medicinal Chemistry;2024-08-21

2. Targeted Treatment of Various Cancers using Radionuclide: Advancement and Prospective;Current Cancer Therapy Reviews;2024-05-31

3. Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma;2024-05-28

4. Enhanced Theranostic Efficacy of ⁸⁹Zr and ¹⁷⁷Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice;Molecular Pharmaceutics;2024-04-08

5. ПЭТ-КТ при гематологических злокачественных опухолях: что достигнуто и к чему стремиться;Clinical Oncohematology;2024-04-01